Forest Laboratories earnings
Forest Laboratories, Inc. (NYSE:FRX) designs and manufactures ethical drugs. The firm has drugs that treat high blood pressure, Alzheimer’s, and pulmonary disease among other conditions. The firm has many different drugs at different stages of development.
Forest Laboratories, Inc. (NYSE:FRX) earnings will likely not hit their 2012 levels for years, but investors seem confident that the company can grow at a reasonable rate until it does regain those losses. The firm’s stock was close to 52 week high when it closed on Monday afternoon.
Forest Laboratories performance
Since 2013 opened, shares in Forest Laboratories, Inc. (NYSE:FRX) have performed well. The company’s stock has appreciated by 25% since January 1, benefiting from a booming stock market and better than expected earnings in April and July. The growth in the value of the company’s stock has stalled in the last three months as taper talk and a difficult political climate took hold of the stock market.
In August, Mohnish Pabrai took part in Brown University's Value Investing Speaker Series, answering a series of questions from students. Q3 2021 hedge fund letters, conferences and more One of the topics he covered was the issue of finding cheap equities, a process the value investor has plenty of experience with. Cheap Stocks In the Read More
Shares in Forest Laboratories, Inc. (NYSE:FRX) are currently trading at more than 45 times expected 2014 earnings. The company is expected to expand quickly in the coming years as its brand of ethical pharmaceuticals take off. Later on this morning, at !0 AM EDT, Forest Labs executives will host a conference call to discuss this earnings report.